Skip to main content

Table 5 AE type and outcomes for AEs grade 1–3

From: Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia

  AE grade System Organ Class (SOC)/AE type AE outcome Treatment interruption Improvement after interr Treatment restart Alternative cause for AE
   General disorders Vascular disorders Musculo-Skeletal disorders Nervous System & Psychiatric disorders Renal disorders Gastroint. disorders Reproduct system disorders Skin disorders      
BZB 1   1 enlarged PAVM 1 joint pain
1 facial pain
     2 hair loss 1 unresolved/worsened
4 resolved
1 Yes
4 No
1 No 1 No In 2
2 1 fatigue 2 hypertension 6 joint pain
1 vertebral fracture
1 confusion
3 headaches
2 proteinuria 1 diarrhea    17 resolved 17 No    In 1
3 1 fatigue 3 hypertension
1 arterial thrombosisa
2 joint pain 1 confusion   1 GI bleedingb
1 diarrhea
   1 unresolved/worsened
9 resolved
3 Yes
7 No
2 Yes
1 No
1 Yes
2 No
In 2
TH 1     5 peripheral neuropathyc
1 somnolence
1 drowsiness
    1 rash 2 unresolved/worsened
6 resolved
3 Yes
5 No
3 Yes 3 No none
2     5 peripheral neuropathyd
4 dizziness
2 somnolence
7 drowsiness
  1 constipation 1 erectile dysfunction   7 unresolved/worsened
2 resolved with sequelae
11 resolved
15 Yes
5 No
10 Yes
5 No
15 No none
3 1 limb edema 1 arterial thrombosisf   2 peripheral neuropathy &
2 dizziness
     4 unresolved/worsened
2 resolved
4 Yes
2 No
2 Yes
2 No
1 Yes
3 No
In 1
  1. Legend: aunresolved/worsened after treatment interruption
  2. bresolved completely
  3. c3 resolved completely, 2 unresolved/worsened,
  4. d1 resolved completely, 1 resolved with sequelae, 3 unresolved/worsened
  5. &2 unresolved/worsened
  6. fresolved completely